drugset / Trial / NCT01543763
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Phase 1
Completed
90 enrolled
Pamela Munster
GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease · collabNovartis · collabPharmacyclics LLC. · collabXynomic Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.
Timeline
- Start
- 2012-06-25
- Primary completion
- 2024-01-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abexinostat | Small molecule | 30 mg/m2 | Oral |
| Subject | Abexinostat | Small molecule | 75 mg/m2 | Oral |
| Subject | Abexinostat | Small molecule | 400 mg | Oral |
| Subject | Abexinostat | Small molecule | 800 mg | Oral |